Binimetinib
Product Description
OMGENE LIFE SCIENCES PRIVATE LIMITED
-
Country/Region:India
-
On CPHI since:2020
-
Certificates:1
-
Employees:100 - 249
Company types
Primary activities
Categories
Specifications
OMGENE LIFE SCIENCES PRIVATE LIMITED
-
Country/Region:India
-
On CPHI since:2020
-
Certificates:1
-
Employees:100 - 249
Company types
Primary activities
More Products from OMGENE LIFE SCIENCES PRIVATE LIMITED (44)
-
Product Rezafungin
Rezafungin is a next-generation, semi-synthetic, cyclic lipopeptide and echinocandin derivative, with potential antifungal activity. -
Product Tirzepatide
Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
-
Product Cetrorelix Acetate
Indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. -
Product Degarelix Acetate
Indicated for treatment of patients with advanced prostate cancer. -
Product Apremilast
Indicated in Psoriatic Arthritis, Psoriasis and Oral Ulcers Associated with Behçet’s Disease -
Product Bedaquiline Fumarate
Diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). -
Product Brivaracetam
Indicated for the treatment of partial-onset seizures in patients 4 years of age and older. -
Product Carbetocin
Used to prevent excessive bleeding after childbirth, particularly following Cesarean section. -
Product Crisaborole
Indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. -
Product Deutetrabenazine
Indicated for the treatment of chorea associated with Huntington’s disease, tardive dyskinesia in adults.
-
Product Erdafitinib
Indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has susceptible FGFR3 or FGFR2 genetic alterations, and progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuva... -
Product Etelcalcetide
Iindicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.











